Wikipedia

Dravet syndrome

(Redirected from Severe myoclonic epilepsy of infancy)

Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever.[1] It is very difficult to treat with anticonvulsant medications. It often begins before one year of age,[1] with six months being the age that seizures, char­ac­ter­ized by prolonged convulsions and triggered by fever, usually begin.[2]

Dravet syndrome
Other namesSevere myoclonic epilepsy of infancy, severe polymorphic epilepsy of infancy, borderland SMEI (SMEB), borderline SMEI, intractable childhood epilepsy with generalised tonic clonic seizures (ICEGTCS)
Pronunciation
SpecialtyNeurology

Seizures are the most common form of DS.[2] DS is diagnosed clinically and genetic testing is recommended if there is any doubt.[2] Due to drug-refractory epilepsy in DS, many other therapies are being explored to prolong the life expectancy of patients.[3]

Signs and symptoms

edit

Dravet syndrome has been characterized by prolonged febrile and non-febrile seizures within the first year of a child's life. This disease progresses to other seizure types like myoclonic and partial seizures, psychomotor delay, and ataxia.[4] It is characterized by cognitive impairment, behavioural disorders, and motor deficits.[5] Behavioural deficits often include hyperactivity and impulsiveness, and in more rare cases, autistic-like behaviours.[5] Dravet syndrome is also associated with sleep disorders including somnolence and insomnia.[5] The seizures experienced by people with Dravet syndrome become worse as the patient ages, as the disease is not very observable when symptoms first appear.[5] This coupled with the range of severity differing between each individual diagnosed and the resistance of these seizures to drugs has made it challenging to develop treatments.[5]

Dravet syndrome appears during the first year of life, often beginning around six months of age with frequent febrile seizures (fever-related seizures). Children with Dravet syndrome typically experience a lagged development of language and motor skills, hyperactivity and sleep difficulties, chronic infection, growth and balance issues, and difficulty relating to others. The effects of this disorder do not diminish over time, and children diagnosed with Dravet syndrome require fully committed caretakers with tremendous patience and the ability to closely monitor them.[6]

Febrile seizures are divided into two categories known as simple and complex. A febrile seizure would be categorized as complex if it has occurred within 24 hours of another seizure or if it lasts longer than 15 minutes. A febrile seizure lasting less than 15 minutes would be considered simple. Sometimes modest hyperthermic stressors like physical exertion or a hot bath can provoke seizures in affected individuals.[6] However, any seizure uninterrupted after 5 minutes, without a resumption of postictal (more normal; recovery-type; after-seizure) consciousness can lead to potentially fatal status epilepticus.[citation needed]

Causes

edit

In most cases the mutations in Dravet syndrome are not hereditary and the mutated gene is found for the first time in a single family member.[4] In 70–90% of patients, Dravet syndrome is caused by nonsense mutations in the SCN1A gene resulting in a non-functional protein.[4] This gene codes for neuronal voltage-gated sodium channel Nav1.1.[7] In mouse models, these loss-of-function mutations have been observed to result in a decrease in sodium currents and impaired excitability of GABAergic interneurons of the hippocampus.[7] The researchers found that loss of Nav1.1 channels was sufficient to cause the epilepsy and premature death seen in Dravet syndrome.[7][3]

The timing of the first signs and symptoms in Dravet syndrome occur about the same time as normal childhood vaccinations, leading some to believe the vaccine was the cause. However, this is likely a non-specific response to fever, as vaccination often induces fever,[8] and fever is known to be associated with seizures in persons with Dravet syndrome.[9] Some of the patients who put forth vaccine injury claims from encephalopathy were later found, upon testing, to actually have Dravet syndrome.[10]

Genetics

edit

The genotypic explanation of the disorder has been located on the specific voltage-gated sodium channel genes known as SCN1A. This gene is located on the long (q) arm of chromosome 2 at position 24.3 and code for the alpha subunit of the transmembrane sodium channel protein. A mutation this gene will cause an individual to develop dysfunctional sodium channel Nav 1.1, which is crucial in the pathway for sending chemical signals in the brain, causing the phenotypic display of myoclonic epilepsy from the individual. A properly functioning channel would respond to a voltage difference across the membrane and form a pore through which only sodium ions can pass. The influx of sodium induces the generation of action potential by temporarily changing the electrochemical equilibrium of the cell. When the gene is mutated, the eventually translated protein improperly folds its pore segment within the cell membrane because it has different amino acid chemistry, which renders the channel inactive. It is also possible for a mutation to reduce the number of channels produced by an individual, which leads to the development of Dravet syndrome. Both disfunctions, incorrect folding or transcribing less amount of protein, can cause Dravet syndrome.[11]

Currently, the SCN1A gene is the most clinically relevant; the largest number of DS-related mutations characterized thus far occur in this gene.[6][12] Typically, a missense mutation in either the S5 or S6 segment of the sodium channel pore results in a loss of channel function and the development of Dravet syndrome. A heterozygous inheritance of an SCN1A mutation is all that is necessary to develop a defective sodium channel; patients with Dravet syndrome will still have one normal copy of the gene.[11]

Dravet syndrome is generally associated with mutations in the SCN1A gene, but it can also be found in patients with other mutations. Likewise, the presence of a mutation in the SCN1A gene does not necessarily mean that the patient has Dravet syndrome.

- SCN2A: This gene encodes the alpha-2 subunit of the sodium ion channel (Nav1.2). The expression of this gene increases throughout childhood (unlike SCN1A, which peaks at 7–9 months) and is primarily produced in hippocampal neurons. Mutations in the SCN2A gene have been found in patients with various syndromes, and unlike SCN1A mutations, patients often respond to sodium channel blockers.

- SCN8A: This gene encodes the alpha-8 subunit (Nav1.6) and is primarily expressed in excitatory neurons (unlike SCN1A, which is inhibitory). The clinical presentation is distinct from Dravet syndrome, and patients sometimes experience epileptic spasms (not typically observed in Dravet syndrome), are less susceptible to fever-related seizures, generally do not have myoclonic seizures, and often respond to sodium channel blockers.

- SCN9A: This gene encodes the alpha-9 subunit (Nav1.7), expressed in cells of the dorsal root ganglia, neuroendocrine cells, and smooth muscle. Mutations in this gene cause sensory disorders, including an abnormal response to pain. Some Dravet syndrome patients have been found to have mutations in the SCN9A gene, but there is likely a more polygenic cause of Dravet syndrome in these cases.

- SCN1B: This gene encodes the beta-1 subunit of the sodium ion channel, which regulates sodium channel entry on the outer side of the cell membrane. Mutations in the SCN1B gene have been found in several patients with Generalized Epilepsy with Febrile Seizures Plus (GEFS+), but very few with Dravet syndrome.

- PCDH19: This gene, located on the X chromosome, encodes protocadherin 19, a protein that helps neurons adhere to each other as they migrate to form networks and recognize other cells. Because males only possess one copy of the X chromosome, even if this mutation occurs in males, it creates a type of cells containing functional protocadherin 19, so no problems occur. However, it is believed that females (who have two X chromosomes) are affected when one copy is mutated and the other is normal. Therefore, two different populations of cells containing protocadherin 19 are generated, and their abnormal interactions are believed to cause the disease's symptoms. Epilepsy with Mental Retardation limited to Females (EFMR) is its own syndrome, primarily affecting females, although it mimics and resembles Dravet syndrome in several aspects. Seizure onset is later in this epilepsy (an average of about 11 months versus the average of 6 months in Dravet syndrome), photosensitivity is less common, seizure clusters are more frequent and respond to steroids, an approach not used in Dravet syndrome.

- GABRA1: GABA is the primary neurotransmitter. The receptors on neurons that accept this neurotransmitter are called "GABR" (R for receptor) and are divided into two groups: A and B. GABRA1 encodes the alpha-1 receptor, and mutations are found in several epilepsies, including Childhood Absence Epilepsy, Juvenile Myoclonic Epilepsy, and Genetic Generalized Epilepsy. Some cases of Dravet syndrome are associated with mutations in the GABRA1 gene.

- GABRG2: This gene encodes the GABA gamma-2 receptor, and mutations have been found in patients with Generalized Epilepsy with Febrile Seizures Plus (GEFS+), as well as in some Dravet syndrome patients.

- STXBP1: This gene encodes the syntaxin-binding protein 1, which is involved in the vesicle fusion process (sacs containing substances like neurotransmitters) of the cell with the membrane. Therefore, mutations in this gene can affect the cell's ability to release neurotransmitters. Mutations have been found in patients with Ohtahara syndrome, West syndrome, and non-specific epilepsies with variable components of intellectual disability and movement disorders.

- HCN1: This gene encodes a non-selective positive ion channel (allowing the passage of calcium, potassium, and other positive ions), and mutations generally result in a gain of function. In some Dravet patients with HCN1 mutation, the presentation is similar to classic Dravet syndrome.

- CHD2: This gene encodes the chromodomain helicase DNA-binding protein 2, which modifies gene expression. All patients diagnosed as Dravet syndrome with CHD2 mutations began their epilepsy later than usual (ages 1, 2, and 3 years), which generally seems to be a common feature of CHD2 mutations. It has also been described in patients with Jeavons syndrome, Lennox-Gastaut syndrome, and other epilepsies.

- KCNA2: This gene encodes a delayed potassium channel that helps a neuron repolarize after activation. Patients believed to have Dravet syndrome with this mutation managed to remain seizure-free in adulthood, a result that is often not achieved in classic Dravet syndrome.[13][14]

Diagnosis

edit

According to the Dravet Syndrome Foundation, the diagnostic criteria for DS requires the patient to present with several of the following symptoms:[15]

  • Onset of seizures in the first year of life in an otherwise healthy infant
  • Initial seizures are typically prolonged and are generalized or unilateral
  • Presence of other seizure types (i.e. myoclonic seizures)
  • Seizures associated with fever due to illness or vaccinations
  • Seizures induced by prolonged exposure to warm temperatures
  • Seizures in response to strong lighting or certain visual patterns
  • Initially normal EEGs and later EEGs with slowing and severe generalized polyspikes
  • Normal initial development followed by slow development during the first few years of life
  • Some degree of hypotonia
  • Unstable gait and balance issues
  • Ankle pronation and flat feet and/or development of a crouched gait with age

Treatment

edit

Seizures in Dravet syndrome can be difficult to manage but may be reduced by anticonvulsant medications such as clobazam, stiripentol, topiramate and valproate.[16] Because the course of the disorder varies from individual to individual, treatment protocols may vary. A diet high in fats and low in carbohydrates may also be beneficial, known as a ketogenic diet. Although diet adjustment can help, it does not eliminate the symptoms. Until a better form of treatment or cure is discovered, those with this disease will have myoclonic epilepsy for the rest of their lives.[6]

Certain anticonvulsant medications that are classed as sodium channel blockers are now known to make seizures worse in most Dravet patients. These medications include carbamazepine, gabapentin, lamotrigine, and phenytoin.[17]

As there are still very few randomized controlled trials (RCTs) available, evidence-based therapy remains difficult: RCTs are now only available for the drugs fenfluramine (FFA), cannabidiol (CBD), and stiripentol (STP). A North American consensus panel and, more subsequently, a European expert committee both established treatment guidelines.[18]

As a first-line medication, valproic acid (VPA) is recommended in both published recommendations. The American recommendations provide clobazam (CLB) monotherapy as an alternative; however, very few European facilities would use it. It is a prevalent misconception that since the first seizures are typically hemiclonic (focal), antiseizure medicine (ASM) can be a good choice for focal seizures. However, using sodium channel blockers is not recommended as it is can lead to fatal results over an extended period.[18]

Children may experience fewer seizures and less severe (longer-lasting) seizures as a result of first-line therapy with VPA; however, it is uncommon for them to live a life free of seizures. According to the recommendations, second-line options include the ketogenic diet (KD), topiramate (TPM), and STP combined with VPA and CLB. The more current European recommendations now mention CBD and FFA as potential second-line treatments (in Europe, CLB and CBD are combined).[18]

Treatments include cognitive rehabilitation through psychomotor and speech therapy.[5] In addition, valproate is often administered to prevent recurrence of febrile seizures and a benzodiazepine is used for long lasting seizures, but these treatments are usually insufficient.[19]

Stiripentol was the only medication for which a double-blind placebo-controlled randomized controlled trial was performed and this medication showed efficacy in trials.[19] It acts as a GABAergic agent and as a positive allosteric modulator of GABAA receptor.[19] Stiripentol, which can improve focal refractory epilepsy, as well as Dravet's syndrome, supplemented with clobazam and valproate was approved in Europe in 2007 as a therapy for Dravet syndrome and has been found to reduce overall seizure rate by 70%.[19] In cases with more drug-resistant seizures, topiramate and the ketogenic diet are used as alternative treatments.[19] A Cochrane review first published in 2014 and updated 2022 called for larger, randomized, well controlled trials to be able to draw conclusions.[20]

Cannabidiol (CBD) was approved in United States for treatment of Dravet syndrome in 2018.[21] A 2017 study showed that the frequency of seizures per month decreased from 12 to 6 with the use of cannabidiol, compared with a decrease from 15 to 14 with placebo.[22]

In 2020, fenfluramine was approved for the medical treatment in the European Union and the USA.[23][24][25]

Approaching seizures in adults

edit

Regarding the care of adult DS patients, no particular guidelines are available. The usage of VPA, CLB, and TPM continued through childhood, adolescence, and adulthood, although that of STP decreased with age (31% in adults), according to the findings of a survey of caretakers of patients with DS on their experiences with management and health services. According to reports, only a tiny percentage of adult patients receive treatment with sodium channel blockers, even though many of them had already been exposed to this class of ASM. It has been shown that certain DS patients may respond to sodium channel blockers, especially LTG, with a greater frequency of seizures noted upon halting the medication.[18]

Prior to the age of 20, photosensitivity and pattern sensitivity each have a tendency to vanish; nevertheless, some individuals still displayed light sensitivity. Consequently, for those who are older, triggering variables ought to be minimized.[18]

Disease-modifying therapies

edit

Modifying therapeutics are those which seek to correct the underlying cause of the disease. These types of treatments are into the known “advanced therapies”.

Stoke Therapeutics developed STK-001 is an antisense oligonucleotide (ASOs) that can modify gene expression in the nervous system. The FDA approved ASOs for treatment of ten genetic disorders. The technique consists of targeted augmentation of nuclear gene output which allows to selectively boost expression only in tissues where the protein is normally expressed. STK-001 can increase the level of productive SCN1A mRNA and consequently increase the expression of sodium channel gene SCN1A.[26]

Stoke Therapeutics is currently evaluating the long-term safety and tolerability of repeated doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status and quality of life will be measured as secondary endpoints in this open-label study. Recently, the company announced positive results of MONARCH and ADMIRAL in which patients received 3 doses of STK-001 and were observed for 6 months.[27]

In parallel, Encoded Therapeutics is developing an adeno-associated virus serotype 9 (AAV9) SCN1A gene regulation therapy. It has been designed to target transgene expression to GABAergic inhibitory neurons and reduce off-target expression within excitatory cells. In this case, the treatment would be administered as a single dose intracerebroventricularly. This company has started a clinical trial in phase 1 and 2 to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to 36 months.[28]

Prognosis

edit

Numerous research studies have been performed to evaluate DS prognosis. According to two studies, status epilepticus and sudden unexpected death in epilepsy (SUDEP) are the two most frequent causes of premature fatality among DS patients. Between ten and twenty percent of people with DS are thought to pass away before 10 years of age. The International Dravet Syndrome Epilepsy Action League (IDEA League) conducted a study in which they concluded that 31 of 833 DS patients passed away within 10 years. The average death age was 4.6 years, with 19 of 31 deaths because of SUDEP, 10 from status epilepticus, 1 from ketoacidosis, and 1 from an accident. It is unclear what duration generally these patients are projected to live. A prospective study of 37 individuals showed that, by reducing status epilepticus from occurring at a young age, the prognosis for seizures and mental impairment in DS patients can be improved.[29]

Epidemiology

edit

Dravet syndrome is a severe form of epilepsy. It accounts for roughly 10% of cases of epileptic encephalopathies in children.[30] It is a rare genetic disorder that affects an estimated 1 in every 20,000–40,000 births.[31][32]

COVID-19

edit

Although it is not clear whether people with Dravet syndrome are specially vulnerable to COVID-19 infection, recent publications have shown that affected individuals and their families have suffered some indirect consequences during the COVID-19 pandemic, such as healthcare barriers, loss of therapies or economic issues.[33]

History

edit

Charlotte Dravet first described severe myoclonic epilepsy of infancy in Centre Saint Paul, Marseille, France, in 1978; the name was later changed to Dravet syndrome in 1989.[34] Similar descriptions were given by Bernardo Dalla Bernardina in Verona.[35]

Charlotte Figi, who was diagnosed as having Dravet syndrome, was the focus of a cause célèbre to provide a means for use of cannabidiol for persons with intractable seizures. She died from pneumonia, possibly caused by COVID-19, in April, 2020.[36]

References

edit
  1. ^ a b Shorvon SD, Guerrini R, Cook M, eds. (2013). Oxford textbook of epilepsy and epileptic seizures. Oxford: Oxford Univ. Press. p. 13. ISBN 978-0-19-965904-3.
  2. ^ a b c McIntosh AM, McMahon J, Dibbens LM, Iona X, Mulley JC, Scheffer IE, Berkovic SF (June 2010). "Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study". The Lancet. Neurology. 9 (6): 592–8. doi:10.1016/S1474-4422(10)70107-1. PMID 20447868. S2CID 2676315. ProQuest 314128956.
  3. ^ a b Couzin-Frankel J (8 April 2015). "Sudden death in epilepsy: Researchers finger possible cause". Science. doi:10.1126/science.aab2456.
  4. ^ a b c Selmer KK, Eriksson AS, Brandal K, Egeland T, Tallaksen C, Undlien DE (October 2009). "Parental SCN1A mutation mosaicism in familial Dravet syndrome". Clinical Genetics. 76 (4): 398–403. doi:10.1111/j.1399-0004.2009.01208.x. PMID 19673951. S2CID 40396775.
  5. ^ a b c d e f Granata T (April 2011). "Comprehensive care of children with Dravet syndrome". Epilepsia. 52 (Suppl 2): 90–94. doi:10.1111/j.1528-1167.2011.03011.x. PMID 21463289. S2CID 573375.
  6. ^ a b c d Miller IO, de Menezes MA (April 2019). "SCN1A seizure disorders.". GeneReviews®[Internet]. Seattle: University of Washington. PMID 20301494.
  7. ^ a b c Cheah C, Catterall WA (2012). Characterizing the role of sodium channels in mouse models of Dravet Syndrome (Ph.D. thesis). Seattle, Washington: University of Washington.
  8. ^ Lin YJ, Wen CN, Lin YY, Hsieh WC, Chang CC, Chen YH, et al. (January 2020). "Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis". Nature Communications. 11 (1): 315. Bibcode:2020NatCo..11..315L. doi:10.1038/s41467-019-14230-x. PMC 6965081. PMID 31949137.
  9. ^ "What is Dravet Syndrome?". Cherry Hill, NJ: Dravet Syndrome Foundation, Inc. 10 January 2022.
  10. ^ Ben-Menachem E (July 2011). "Vaccination and the onset of dravet syndrome". Epilepsy Currents. 11 (4): 120–122. doi:10.5698/1535-7511-11.4.120. PMC 3152151. PMID 21852883.
  11. ^ a b Wallace R (2005). "A plethora of SCN1A mutations: what can they tell us?". Epilepsy Currents. 5 (1): 17–20. doi:10.1111/j.1535-7597.2005.05105.x. PMC 1176321. PMID 16059449.
  12. ^ Sugawara T, Tsurubuchi Y, Agarwala KL, Ito M, Fukuma G, Mazaki-Miyazaki E, et al. (May 2001). "A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction". Proceedings of the National Academy of Sciences of the United States of America. 98 (11): 6384–6389. Bibcode:2001PNAS...98.6384S. doi:10.1073/pnas.111065098. PMC 33477. PMID 11371648.
  13. ^ Steel D, Symonds JD, Zuberi SM, Brunklaus A (November 2017). "Dravet syndrome and its mimics: Beyond SCN1A". Epilepsia. 58 (11): 1807–1816. doi:10.1111/epi.13889. PMID 28880996.
  14. ^ "Síndrome de Dravet: Causas, síntomas y tratamiento". Fundación Síndrome de Dravet (in Spanish). Retrieved 2023-10-27.
  15. ^ "Diagnostic Criteria". Dravet Syndrome Foundation. Archived from the original on 17 March 2015. Retrieved 17 March 2015.
  16. ^ "Dravet Syndrome Foundation: Treatment". Archived from the original on 28 December 2015. Retrieved 1 January 2016.
  17. ^ "NICE: Epilepsies: diagnosis and management". The National Institute for Health and Care Excellence (NICE). 11 January 2012. Retrieved 1 January 2016.
  18. ^ a b c d e Cardenal-Muñoz E, Auvin S, Villanueva V, Cross JH, Zuberi SM, Lagae L, Aibar JÁ (March 2022). "Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe". Epilepsia Open. 7 (1): 11–26. doi:10.1002/epi4.12569. PMC 8886070. PMID 34882995.
  19. ^ a b c d e Chiron C, Dulac O (April 2011). "The pharmacologic treatment of Dravet syndrome". Epilepsia. 52 (Suppl 2): 72–75. doi:10.1111/j.1528-1167.2011.03007.x. PMID 21463285. S2CID 39978156.
  20. ^ Brigo F, Igwe SC, Bragazzi NL (September 2022). "Stiripentol add-on therapy for drug-resistant focal epilepsy". The Cochrane Database of Systematic Reviews. 2022 (9): CD009887. doi:10.1002/14651858.CD009887.pub6. PMC 9447417. PMID 36066395.
  21. ^ "Press Announcements - FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy". www.fda.gov. Retrieved 27 June 2018.
  22. ^ Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. (May 2017). "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome". The New England Journal of Medicine. 376 (21): 2011–2020. doi:10.1056/NEJMoa1611618. hdl:20.500.11820/2ed5e0db-7de9-4411-93d7-3a5c388006b9. PMID 28538134. S2CID 86481485.
  23. ^ Fintepla, on ema.europa.eu
  24. ^ Fintepla (fenfluramine). An overview of Fintepla and why it is authorised in the EU, on ema.europa.eu
  25. ^ FDA Approves New Therapy for Dravet Syndrome, on fda.gov
  26. ^ Hill SF, Meisler MH (2021). "Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders". Developmental Neuroscience. 43 (3–4): 247–252. doi:10.1159/000517686. PMC 8440367. PMID 34412058.
  27. ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 2023-10-27.
  28. ^ Lersch R, Jannadi R, Grosse L, Wagner M, Schneider MF, von Stülpnagel C, et al. (April 2022). "Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome". The Neuroscientist. 29 (6): 732–750. doi:10.1177/10738584221088244. PMC 10623613. PMID 35414300.
  29. ^ Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P (June 2019). "Dravet Syndrome: An Overview". Cureus. 11 (6): e5006. doi:10.7759/cureus.5006. PMC 6713249. PMID 31497436.
  30. ^ Berkovic SF (December 2019). "Epileptic encephalopathies of infancy: welcome advances". Lancet. 394 (10216): 2203–2204. doi:10.1016/S0140-6736(19)31239-5. PMID 31862247. S2CID 209394550.
  31. ^ Hurst DL (August 1990). "Epidemiology of severe myoclonic epilepsy of infancy". Epilepsia. 31 (4): 397–400. doi:10.1111/j.1528-1157.1990.tb05494.x. PMID 1695145. S2CID 31868578.
  32. ^ Yakoub M, Dulac O, Jambaqué I, Chiron C, Plouin P (September 1992). "Early diagnosis of severe myoclonic epilepsy in infancy". Brain & Development. 14 (5): 299–303. doi:10.1093/brain/aws151. PMID 1456383.
  33. ^ Aledo-Serrano Á, Mingorance A, Jiménez-Huete A, Toledano R, García-Morales I, Anciones C, Gil-Nagel A (June 2020). "Genetic epilepsies and COVID-19 pandemic: Lessons from the caregiver perspective". Epilepsia. 61 (6): 1312–1314. doi:10.1111/epi.16537. PMC 7276740. PMID 32420620.
  34. ^ Dravet C (April 2011). "The core Dravet syndrome phenotype". Epilepsia. 52 (Suppl 2): 3–9. doi:10.1111/j.1528-1167.2011.02994.x. PMID 21463272. S2CID 41553756.
  35. ^ "Bernardo Dalla Bernardina | University of Verona (UNIVR)". ResearchGate.
  36. ^ Ingold J (April 8, 2020). "Charlotte Fiji". The Colorado Sun. Retrieved April 13, 2020. Charlotte Figi, the Colorado Springs girl who, as a gleeful and fragile child, launched a movement that led to sweeping changes in marijuana laws across the globe, has died from complications possibly related to the new coronavirus.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dravet_syndrome&oldid=1252597693"